Dimensional Fund Advisors LP Acquires 412,372 Shares of Gilead Sciences, Inc. (GILD)
Dimensional Fund Advisors LP raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 4,039,848 shares of the biopharmaceutical company’s stock after acquiring an additional 412,372 shares during the period. Dimensional Fund Advisors LP’s holdings in Gilead Sciences were worth $327,306,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also bought and sold shares of GILD. Welch Investments LLC purchased a new position in Gilead Sciences during the third quarter valued at approximately $108,000. Horan Capital Advisors LLC. purchased a new position in Gilead Sciences during the third quarter valued at approximately $144,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Gilead Sciences during the second quarter valued at approximately $147,000. Hanson & Doremus Investment Management grew its stake in Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 1,613 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. grew its stake in Gilead Sciences by 29.3% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 480 shares in the last quarter. Hedge funds and other institutional investors own 76.11% of the company’s stock.
Several brokerages recently commented on GILD. Vetr cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $91.25 price objective for the company. in a research note on Monday. Citigroup raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating and reduced their price objective for the company from $88.80 to $76.00 in a research note on Tuesday. Morgan Stanley reaffirmed an “equal weight” rating and set a $83.00 price objective (up previously from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. Bank of America reduced their price objective on shares of Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating for the company in a research note on Wednesday, October 4th. Finally, Jefferies Group reaffirmed a “hold” rating and set a $93.00 price objective on shares of Gilead Sciences in a research note on Wednesday, October 4th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eighteen have issued a buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus target price of $85.58.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business’s quarterly revenue was down 13.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.75 EPS. equities research analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
In other news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $74.64, for a total value of $1,119,600.00. Following the completion of the sale, the executive vice president now directly owns 70,988 shares in the company, valued at approximately $5,298,544.32. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 503,333 shares of company stock valued at $37,834,758. Company insiders own 1.30% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://theolympiareport.com/2018/01/31/dimensional-fund-advisors-lp-acquires-412372-shares-of-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.